EUVIMEDEUVIMED entdecken
Crossref

Impact of sintilimab plus anlotinib on progression-free survival in advanced unresectable hepatocellular carcinoma

Cai Sheng, Huan Li

World Journal of Gastrointestinal Oncology · 06.05.2026

DOI: 10.4251/wjgo.119966 ↗

Kurz gefasst

Fachartikel in der Zeitschrift World Journal of Gastrointestinal Oncology, online erschienen am 06.05.2026. Verfasst von Cai Sheng und 1 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND Hepatocellular carcinoma (HCC) has a poor prognosis in advanced unresectable stages, and sintilimab monotherapy has limited efficacy for it. Anlotinib monotherapy has demonstrated certain anti-tumor efficacy and manageable safety in the second-line and above treatment of advanced unresectable HCC, yet its single-agent effect is still limited for long-term disease control. Anti-angiogenic anlotinib synergizes with immunotherapy, but relevant clinical evidence for their combination in advanced unresectable HCC is insufficient. We hypothesized this combination could improve patients’ survival outcomes with acceptable safety. AIM To analyze sintilimab plus anlotinib’s impact on advanced unresectable HCC (uHCC) patients’ progression-free survival (PFS). METHODS Of 90 advanced uHCC patients were split into two groups (45 each): Sintilimab monotherapy vs its combination with anlotinib (sintilimab q3w, anlotinib 2w on/1w off). SPSS 26.0 was used for t -test, χ 2-test, Kaplan-Meier and Cox regression analyses. RESULTS Baselines were comparable (P > 0.05). The combination group had longer median PFS (8.9 ± 0.4 months vs 4.7 ± 0.5 months, P 0.05). Cox analysis identified treatment regimen, Barcelona Clinical Stage of Liver Cancer stage and Eastern Cooperative Oncology Group score as independent PFS factors (P < 0.05). CONCLUSION Sintilimab plus anlotinib exerts better efficacy for advanced uHCC than monotherapy with similar safety.

Zitieren

APA

Sheng, C., & Li, H. (2026). Impact of sintilimab plus anlotinib on progression-free survival in advanced unresectable hepatocellular carcinoma. World Journal of Gastrointestinal Oncology. https://doi.org/10.4251/wjgo.119966

Vancouver

Sheng C, Li H. Impact of sintilimab plus anlotinib on progression-free survival in advanced unresectable hepatocellular carcinoma. World Journal of Gastrointestinal Oncology. 2026. doi:10.4251/wjgo.119966

BibTeX
@article{Sheng2026,
  author = {Sheng, Cai and Li, Huan},
  title = {Impact of sintilimab plus anlotinib on progression-free survival in advanced unresectable hepatocellular carcinoma},
  journal = {World Journal of Gastrointestinal Oncology},
  year = {2026},
  doi = {10.4251/wjgo.119966}
}
Kostenlos starten →